international prognostic score (IPS)

International prognostic score in advanced Hodgkin’s lymphoma

LYMPHOID TUMORS , , , ,

K.D. Kaplanov1, A.L. Shipaeva1, V.A. Vasil’yeva1, E.G. Gemdjian2, I.V. Matveeva1, L.S. Tregubova1, T.U. Klitochenko1, K.V. Demidenko1, O.B. Kalashnikova1, G.U. Vyskub1, O.E. Golubeva1, O.V. Levina1, V.A. Orlov1, and E.A. Demina3

1 Volgograd Regional Oncology Clinic #1, Volgograd, Russian Federation

2 Hematology Research Center, RF Ministry of Health, Moscow, Russian Federation

3 N.N. Blokhin Russian Cancer Research Center, RAMS, Moscow, Russian Federation

ABSTRACT

Since chemotherapy of Hodkgin’s lymphoma was introduced in early 60s, it has undergone fundamental changes that were associated with dramatic improvement in the disease prognosis. Currently, the various intensive modifications of original BEACOPP, such as BEACOPP-14 and escalate BEACOPP, are among the most widely used for treatment of advanced Hodkgin’s lymphoma.

Initially, the International Prognostic Score (IPS) was developed for patients treated with MOPP and MOPP-ABVD protocols. We suggest that due to the well-known changing value of the various prognostic signs with protocols of different intensity, the significance of IPS for BEACOPP-based therapy should be reconsidered.

One hundred seventy two patients with advanced Hodgkin’s lymphoma were included in our trial. All these patients were treated at the Hematology department of Volgograd Regional Oncology Clinic #1. Treatment options were as follows: 64 (37%), 84 (49%), and 24 (14%) patients received intensive BEACOPP-based, standard BEACOPP, or ABVD therapy, respectively. The final data presented are related to the period up to June 30, 2012.

We retrospectively evaluated the treatment outcomes for each IPS group. To distinguish the most significant prognostic signs from all six IPS factors, we studied the impact of each factor on treatment efficacy.

The greatest difference in overall 3- and 4-year survival was observed between the groups of patients with IPS 0–1 and ³ 2; for IPS 0–1, 3- and 4-year overall survival rate was 93%; for IPS ³ 2, 3- and 4-year overall survival rate was 81% and 75%, respectively (p = 0.05). 3-year overall survival was significantly negatively affected by such factors as age over 45 (70% versus 87%, relative risk (RR) = 3.95% CI: 1.7–7, p = 0.01) and albumin level < 40 g/L (79% versus 88%, RR= 2.8, 95% CI: 1.2–6.8, p = 0.02). Overall 3-year survival rate in males (n = 91) and females (n = 81) was 80% and 88%, respectively (p = 0.09). We found no effect on overall and freedom-from-treatment-failure survival (FFTF) of such factors as hemoglobin levels, lymphocyte count, leukocytes count, and IV stage disease. With respect to overall survival, multivariate analysis showed the greatest significance of age (relative risk, RR =3.6, 95% CI: 1.8–7, p = 0.001) and albumin level (OR = 2.6, 95% CI: 1.1–6, p = 0.036).

Keywords: Hodgkin’s lymphoma, international prognostic score (IPS), advanced stages, overall survival (OS), freedom-from-treatment-failure survival (FFTFS), BEACOPP, ABVD

Read in PDF (RUS)pdficon

REFERENCES

  1. Richardson S.E., McNamara C. The management of classical Hodgkin’s lymphoma: past, present, and future. Advant. Hematol. 2011; 2011: 1–17.
  2. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematol. Am. Soc. Hematol. Educ. 2009: 497–506.
  3. Federico M., Luminari S., Iannitto E. et al. ABVD compared with BEACOPP compared with CEC for initial treatment of patients with advanced Hodgkin’s lymphoma: Results from the HD2000 Gruppo Italiani perlo Studio dei Linfomi Trial. Clin. Oncol. 2009; 27: 805–11.
  4. Gianni A.M., Rambaldi A., Zinzani P. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma: a randomized trial of the Michelagelo, GITIL and IIL cooperative groups. ASCO meeting Chicago, 2008. Abstract 8506.
  5. Byar D.P. Identification of prognostic factors. In: Cancer clinical trials. Methods and practice. Ed. by M.E. Buyse, M.J. Staquet, R.J. Sylvester. Oxford: Oxford University Press, 1988.
  6. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s disease. N. Engl. J. Med. 1998; 339(21): 1506–14.
  7. R. Optimal Therapy of Advanced Hodgkin Lymphoma. ASH Education book. 2011: 310–316.
  8. Diehl V., Franklin J., Pfreundschuh M. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. Engl. J. Med. 2003; 348(24): 2386–95.
  9. Wagstaff J., Gregory W.M., Swindell R. et al. Prognostic factors for survival in stage IIIB and IV Hodgkin’s disease: a multivariate analyses comparing two specialist treatment centers. J. Cancer. 1988; 58: 487–92.
  10. Wagstaff J., Steward W., Jones M. et al. Factors affecting remission and survival in patients with advanced Hodgkin’s disease treated with MVPP. Oncol. 1986; 4: 135–47.
  11. Straus D.J., Gaynor J.J., Myers J. et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. Clin. Oncol. 1990; 8: 1173–86.
  12. Proctor S.J., Taylor P., Mackie M.J. et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin’s disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Lymphoma 1992; 7 (Suppl.): 17–20.
  13. Low S.E., Horsman J.M., Walters S.J. et al. Risk-adjusted prognostic models for Hodgkin’s disease (HD) and grade II non- Hodgkin’s lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients. J. Hematol. 2003; 120: 277–80.
  14. Gobbi P.G., Comelli M., Grignani G.E. et al. Estimate of expected survival at diagnosis in Hodgkin’s disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin’s Disease (IDHD). Hematologica 1994; 79: 241–55.
  15. Moccia A.A., Donaldson J., Chhanabhai M. et al. International Prognostic Score in Advanced- Stage Hodgkin’s Lymphoma: Altered Utility in the Modern Era. J. Clin. 2012; 30: 3383–8.
  16. Капланов К.Д., Шипаева А.Л., Васильева В.А. и др. Эффективность программ химиотерапии первой линии при различных стадиях лимфомы Ходжкина. Клин. онкогематол. 2012; 1: 22–9. [Kaplanov K.D., Shipayeva A.L., Vasilyeva V.A. i dr. Effektivnost programm khimioterapii pervoy linii pri razlichnykh stadiyakh limfomy Khodzhkina (Efficacy of first-line chemotherapy programs at various stages of Hodgkin’s disease). onkogematol. 2012; 1: 22–9.]